Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theragenics (TGX) on the up and up -- Ignore unavailable to you. Want to Upgrade?

To: Solid who wrote (853)	5/13/1998 8:04:00 PM
From: Ron Kline	Read Replies (1) \| Respond to of 1055

Anyone get their annual report today. Again a good effort, simple but is well written and addresses all the issues. I like the fact that M. Jacobs is willing to be frank about things they need to work on as well as what they have accomplished. Nice statements about the growth going forward as well as the encouraging clinical trials. These are things that you do not hear about unless you are a doctor in the field or study this research. One thing was interesting is how low the salaries are (comparing to other pharms) and the fact they didn't give her any stock options in 97. I would have thought they would give her a boat load. But I guess if you see what she has she isn't doing bad. Average exercise price of options are like $2. Where was I when that was going on. Anyway overall I see little in the way to stop THRX from continuing to post great results in the future. They need more shares for other splits down the road as they stated so they must see more growth ahead. Ron